Apex

Quick links to important sections

Apex

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Apex

Quick Facts

Property Description
Active ingredient Bicalutamide
Form Film-coated tablet (Oral)
Pharmacological class Non-steroidal Antiandrogen (NSAA)
General purpose Hormonal cancer management
Origin Synthetic compound

The Identity of Apex: Defining Its Class and Substance

The medicine Apex is the trade name for the active substance Bicalutamide, a synthetic, single-ingredient compound classified as an antineoplastic agent. It falls specifically into the pharmacological group known as a Non-steroidal Antiandrogen (NSAA). This classification identifies Apex as a type of endocrine therapy designed to interfere with hormone-driven processes. Apex is a prescription-only medication supplied for oral administration as a film-coated tablet, a non-invasive dosage form used to achieve systemic action in oncological management. Bicalutamide is an antiandrogen agent used in cancer therapy.

Bicalutamide: Composition and Endocrine Purpose

Bicalutamide is the core active ingredient, and its general purpose is to manage malignant conditions that are sensitive to androgens, which are male sex hormones. The primary function of this antiandrogen is to achieve peripheral androgen blockade by acting as an androgen receptor antagonist. This action establishes the drug's therapeutic role. By competitively inhibiting the binding of androgens, Apex helps to limit the proliferation signals that drive certain hormone-dependent prostate carcinoma cells. This mechanism is recognized for its ability to regulate cell growth in specific malignancies, particularly in the context of advanced hormone-sensitive disease.

Physical Form: The Single-Ingredient Oral Tablet

Apex is supplied as an oral film-coated tablet, which is a single-ingredient product. This practical, solid dosage form ensures the active substance, Bicalutamide, is absorbed and distributed throughout the body efficiently. This design is intended for achieving continuous systemic action required for long-term endocrine therapy. The film coating itself is a key differentiating feature, and the fixed-dose oral format ensures convenient daily administration.

Regulatory References

  1. prostate carcinoma

What side effects are possible with Apex?

Possible side effects and safety information

The safety profile of Apex (Bicalutamide) is defined by officially documented adverse reactions categorized by frequency and the physiological systems affected, based on regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse effects are grouped according to their incidence rate as classified in official documents:

  • Very Common (ge 1/10): Reactions frequently observed include hot flush and general weakness (asthenia). Effects on the reproductive system such as gynaecomastia (breast swelling) and breast pain are also very common.
  • Common (ge 1/100 to < 1/10): These include systemic effects like anaemia, central nervous system effects such as dizziness and somnolence, and effects like nausea and rash.
  • Uncommon (ge 1/1,000 to < 1/100): This category includes serious respiratory events such as interstitial lung disease (including pneumonitis and pulmonary fibrosis), with reported fatal outcomes.
  • Rare (< 1/1,000): This classification includes severe hepatobiliary effects such as hepatic failure, with some reported fatal outcomes, and photosensitivity reactions.

Serious Adverse Reactions and Safety Constraints

The most significant risks highlighted in regulatory safety information involve the hepatobiliary and pulmonary systems, including cases of severe hepatic failure and interstitial lung disease. The label also notes an increased risk of ischemic cardiovascular events, including myocardial infarction and heart failure, particularly in patients aged 65 and older. The majority of significant liver changes are often observed within the first six months of treatment.

Safety Restrictions: Apex is formally contraindicated for use in females and pediatric patients. It is also contraindicated in patients with severe hepatic impairment. Periodic liver function testing is formally advised, particularly during the first four months of therapy, to monitor for severe hepatic changes.

Overdose and Emergency Response

Apex Overdose and When to Seek Help — Official Regulatory Information

The official regulatory profile for Apex (Bicalutamide) notes limited human experience with acute overdosage, and the exact oral dose required to produce life-threatening symptoms has not been established. Due to the compound's chemical class, a theoretical risk of methaemoglobinaemia is documented, which may be observed as a cyanotic presentation following severe intoxication.

Mandated Emergency Action Government health authorities mandate immediate contact with emergency services or a poison control helpline whenever an overdose is suspected. Urgent medical help is specifically required if the patient exhibits severe signs, including collapse, seizure, trouble breathing, or inability to be awakened. These conditions are officially recognized triggers for immediate intervention.

Management and Monitoring Requirements There is no specific antidote known for Bicalutamide overdose. Regulatory documents classify the required treatment as symptomatic and mandate general supportive care. In alert patients, vomiting may be induced as a procedural measure. Management also requires frequent monitoring of vital signs and close observation of the patient. If clinical signs suggestive of potential liver dysfunction are noted, the serum transaminases must be measured immediately. Dialysis is officially documented as not likely to be helpful due to the drug’s high degree of protein binding.

Therapeutic Uses of Apex

What Apex Treats: Main Uses and Benefits

Apex (Bicalutamide) is applied within therapeutic domains associated with urological oncology for supportive hormonal management in men with prostate cancer. It offers systemic control and symptomatic support in conditions presenting with systemic or localized discomfort, such as advanced disease.

The primary therapeutic domain is relevant in conditions where functional stability becomes affected by hormone-driven progression, covering advanced, locally extensive, or metastatic disease, and recurrent manifestations. By supporting systemic control, it may assist in easing challenging symptoms related to physical discomfort and contributes to improved day-to-day comfort and physical function.

It is also commonly used in settings marked by temporary physiological imbalance at the start of certain hormonal management, which supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Symptom Support

Apex is considered relevant for alleviating the burden of physical symptoms by supporting systemic control of tumor growth, which contributes to improved day-to-day comfort and physical function.

Regulatory References

  1. MedlinePlus Drug Information from the National Institutes of Health

Eligibility and Restrictions for Use

Who Can and Cannot Use Apex (Bicalutamide)

The population eligibility for Apex is strictly defined by regulatory authorities and is determined by gender, age, pre-existing conditions, and co-administration restrictions.

Eligibility and Exclusion Status

Category Official Regulatory Status
Approved Population Adult males, including the elderly, for the management of prostate cancer.
Females & Pediatric Contraindicated in all women (including those who are pregnant or breastfeeding) and in all children and adolescents.

Conditional Use and Prohibitions

Use is contraindicated for any patient with a known hypersensitivity to bicalutamide or excipients. Patients must not take Apex if they are also using medications such as terfenadine, astemizole, or cisapride. Use is also prohibited for individuals with rare hereditary disorders like galactose intolerance due to the tablet's composition.

Caution is required for patients with moderate to severe hepatic impairment or severe renal impairment due to potential changes in drug accumulation. Furthermore, males with partners of childbearing potential are required to use effective contraception during therapy and for 130 days following treatment.

What should I know about interactions with other medicines?

The regulatory profile for Apex (Bicalutamide) identifies several specific interaction patterns that necessitate restrictions or require monitoring, primarily stemming from its pharmacokinetic properties.

The active component, R-bicalutamide, is officially designated as an inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme. This mechanism results in increased systemic exposure of other medicines metabolized by CYP3A4. Due to this potential risk, co-administration is formally contraindicated with several substances, including Terfenadine, Astemizole, Cisapride, Flibanserin, Lomitapide, and Lonafarnib, as documented in regulatory labeling.

A separate pharmacodynamic interaction is noted with Coumarin anticoagulants, such as Warfarin. Bicalutamide may potentiate the effects of these medicines by displacing them from protein binding sites, an effect that requires monitoring due to the potential for an increase in Prothrombin Time (PT) and International Normalized Ratio (INR).

For combination therapy, the timing rule requires that treatment with Bicalutamide must be initiated simultaneously with LHRH analogues. Furthermore, a population-specific consideration notes that patients with moderate to severe hepatic impairment may experience increased accumulation of R-bicalutamide, which could heighten the clinical significance of these enzyme-mediated interactions. The official profile states that the medication can be taken with or without food.

Mechanism of Action

The action of Apex centers on the Androgen Receptor (AR), a nuclear receptor crucial for cellular signaling. The active component functions as a competitive silent antagonist, physically occupying the AR's ligand-binding site. This prevents potent natural hormones from binding and activating the receptor. This interference modifies the early molecular steps, resulting in the inhibition of androgen-regulated gene expression.

Following receptor binding, the mechanism focuses on transcriptional inactivation. The drug-bound AR complex remains functionally inactive, failing to successfully initiate the required gene expression sequence in the cell nucleus. This process modulates key cellular pathways, reducing AR-mediated transcriptional activity within targeted hormone-responsive cells.

Apex's peripheral action indirectly engages the Hypothalamic-Pituitary-Gonadal (HPG) Axis. By blocking peripheral feedback, the drug's mechanism triggers a compensatory upregulation of pituitary hormones, which causes an increase in the body's circulating testosterone and estradiol levels. The sustained receptor blockade must therefore be maintained to counteract these elevated levels of circulating hormones.

Dosage and Administration Information

Apex (Bicalutamide) is prescribed for oral administration as a film-coated tablet and must be swallowed whole. The medicine is taken once daily at the same time each day, a pattern that helps ensure consistent drug levels for continuous systemic management. The tablets may be taken with or without food, allowing flexibility in the daily schedule.

Dosing regimens depend on the specific treatment context. The standard regimen for use in combination with a Luteinizing Hormone-Releasing Hormone (LHRH) analog is 50 mg taken once per day. A different regimen of 150 mg once daily is used in some regions for locally advanced disease or as monotherapy.

Treatment requires specific timing protocols related to concomitant hormonal therapy. Administration must begin at the same time as, or at least three days before, the start of treatment with an LHRH analog. The duration of therapy is typically continuous. If a daily dose is forgotten, the instruction is to omit the missed dose completely and continue with the next dose at the scheduled time; the next dose must not be doubled. Furthermore, no dose adjustment is necessary for patients with any degree of renal impairment or mild to moderate hepatic impairment, defining a stable usage principle for these populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Apex (Bicalutamide)

Evidence for Advanced Hormone-Sensitive Prostate Cancer (Combination Therapy)

The primary clinical evaluation of Apex was studied for its use in men with metastatic or locally extensive prostate cancer that is still sensitive to hormonal treatment. Randomized Controlled Trials (RCTs) and long-term follow-up studies explored how Bicalutamide performs when added to standard hormonal deprivation therapy. These studies monitored endpoints, including Overall Survival (OS) and the Time to Progression (TTP) of the disease, and monitored the Prostate-Specific Antigen (PSA) biomarker, a measure used in these studies.

Studies reported observations that the use of Bicalutamide in combination with standard hormonal treatment was associated with reported differences in TTP and OS measurements compared to hormonal treatment used alone. Findings generally describe patterns where the combination approach was associated with a reported pattern of lower PSA progression in the observed patient populations. The evidence derived from these trials contributes to the data used for comparison within hormonal management strategies in this advanced disease setting. This research was conducted before the routine use of newer antiandrogens, and thus, further research is needed to contextualize these findings within the use of newer treatments. Long-term effects are not fully established beyond the long reported follow-up periods.

Evidence for Locally Advanced Disease and Recurrence

Research has also explored the role of Apex in situations where the cancer is locally advanced or has shown signs of returning after initial local therapy.

Studies in Locally Advanced Disease Following Local Treatment

For locally advanced prostate cancer, Bicalutamide was studied for its use as an adjuvant therapy following local treatments like radiation. Long-term RCTs research examined how adding Bicalutamide to radiotherapy was associated with outcomes like Progression-Free Survival (PFS) and Overall Survival (OS). Analyses reported that the combination was associated with findings related to progression events, particularly in the locally advanced disease setting. Reports described that patterns in Overall Survival varied across patient subgroups. For men with less extensive local disease, the evidence does not consistently describe the same outcomes. The optimal duration for Bicalutamide use in this specific setting is an area where research is ongoing.

Research on Non-Metastatic Biochemical Recurrence

Apex was also evaluated in men who experienced a rise in their PSA biomarker level after definitive local treatment, but without visible metastases. One major, long-term trial studies explored the difference between taking Bicalutamide or a placebo. Findings from this trial described observations that Bicalutamide was associated with a reported pattern in the time to biochemical recurrence (rising PSA) measurement. Since this core study was conducted many years ago, the applicability of the findings to patients managed with contemporary treatment is limited. Consistency of long-term OS findings across all categories of recurrent disease remains uncertain.

Key Studies & References

  1. Final results of the Bicalutamide Trialists' Group-randomized controlled trial of Bicalutamide 150 mg monotherapy for localized to locally advanced prostate cancer

Frequently Asked Questions (FAQ)

Common questions about Apex (FAQ)


Q: Can Apex make you feel drowsy or affect your ability to drive?

A: Official information indicates that Apex may cause side effects such as dizziness and somnolence, which is the term for drowsiness. Because of these potential effects on the nervous system, regulatory documents advise that patients should be aware of how the medicine affects them before attempting to drive or operate complex machinery.

Q: Does Apex interact with common over-the-counter pain relievers?

A: Apex is known to affect how certain liver enzymes process other medicines, which can change the level of those medicines in the body. While specific common pain relievers are not uniformly listed as a major contraindication, many over-the-counter products may be affected by this enzyme action. Patients are generally advised to discuss all products they take, including over-the-counter pain relievers, with a healthcare provider to check for potential interactions.

Q: Are there any known issues with taking Apex while breastfeeding?

A: The official product information for Apex strictly states that the medicine is contraindicated, meaning its use is forbidden, for all women. This prohibition includes women who are breastfeeding as well as those who are pregnant.

Q: Is it normal to experience a headache when first starting Apex?

A: Studies and official reports of side effects have included headache among the adverse reactions observed in some patients. Concerns about persistent or new side effects are typically addressed by a healthcare professional.

Q: Can Apex interact with common cold or flu medications?

A: Apex is classified as an inhibitor of the CYP3A4 liver enzyme. This means it can raise the levels of other medicines that are processed by this enzyme, and many cold and flu products contain such medicines. Because of this risk, the co-administration of over-the-counter cold or flu products is typically reviewed by a healthcare professional.

Q: Does the time of day I eat affect how Apex is absorbed?

A: Official pharmacokinetics data states that Apex is well absorbed into the body when taken by mouth. There is no evidence of any clinically relevant effect of food on its bioavailability, meaning it can be taken with or without food as described in the administration instructions.

Q: What is the risk of a severe allergic reaction to Apex?

A: The official label notes that Apex is contraindicated if a patient has a known hypersensitivity (severe allergy) to Bicalutamide or any of the inactive ingredients. Severe hypersensitivity reactions such as angioedema (swelling, often of the face or throat) have been reported and would require immediate medical care.

Q: What is the recommended maximum duration of Apex treatment in regulatory guidance?

A: Official regulatory guidance describes that the duration of therapy for Apex is typically continuous. While a formal maximum time limit for treatment is not specified in regulatory documents, treatment is commonly maintained until the underlying condition progresses.

Q: What is the official evidence for Apex's use in younger adults?

A: The medicine is officially approved for use in adult males for the management of prostate cancer. Official documentation confirms that Apex is not approved for use in any person under the age of 18, including children and adolescents.

Q: How long does it typically take to feel the initial effects of Apex?

A: Apex works by reaching a stable, effective concentration in the blood, known as steady state. Due to the active component having a long half-life of approximately one week, it takes time for the medicine to accumulate in the body, and steady state occurs after multiple daily doses.

Q: What are the most commonly reported side effects in official studies?

A: According to regulatory listings, the most commonly reported side effects (Very Common, meaning ge 1/10) are hot flush, general weakness or asthenia, gynaecomastia (breast swelling), and breast pain. These are the reactions most frequently observed in official clinical trials.

Q: What does the official label say about the risk of addiction with Apex?

A: Apex (Bicalutamide) is not classified as a controlled substance under federal regulations. The official product labeling does not include specific warnings or information regarding addiction potential or misuse.

Q: What happens if I stop taking Apex suddenly?

A: Official information mentions that for some patients with metastatic prostate cancer, discontinuation of anti-androgens has been associated with an effect known as 'anti-androgen withdrawal syndrome.' This syndrome has been reported to sometimes lead to a decrease in PSA (a disease biomarker) or clinical improvement. Any decisions regarding discontinuation of therapy are made under the guidance of a healthcare professional.

Q: Does Apex have any known interactions with herbal supplements like St. John's Wort?

A: Apex is processed using the body's CYP450 enzyme system. Herbal products such as St. John's Wort are known to interfere with this same system. Patients typically inform their healthcare provider about all herbal products they use to check for potential enzyme-mediated interactions.

Q: Is there a generic version of Apex available yet?

A: Yes, the active ingredient in Apex, which is Bicalutamide, has been approved by the FDA (and similar bodies globally) and is available as a generic version in many regions.

Q: Do I need to get blood tests done regularly while taking Apex?

A: Yes, official regulatory guidance formally advises that serum transaminase levels (which check liver function) should be measured prior to treatment and monitored at regular intervals, especially during the first few months of therapy. Additional monitoring of blood clotting (PT/INR) is also necessary if the patient is taking certain anticoagulants.

Q: Does Apex affect blood pressure or heart rate?

A: Official reports of side effects have included an increase in blood pressure and changes to the heart's electrical activity, known as QT prolongation. Furthermore, the regulatory label notes a risk of serious ischemic cardiovascular events, such as heart attack, particularly in older patients.

Q: Does Apex affect mood or cause anxiety?

A: Official reports of side effects from clinical studies have included depression as an observed adverse reaction. Changes in mood are observations that are typically reviewed with a healthcare professional.

Q: How long do the effects of one dose of Apex typically last?

A: The half-life of the active component (R-bicalutamide) in the blood is approximately one week. This long half-life supports the medicine's continuous action and its once-daily dosing regimen.

Q: Can Apex be taken with antacids or acid-reducing medications?

A: Apex is generally well-absorbed into the body. While specific warnings are not uniformly given for common antacids or acid-reducing medicines in the label, the use of all co-administered products, including these, is typically reviewed with a healthcare professional to check for any potential interactions.

Q: Does Apex only for severe cases of the condition it treats?

A: No, the official regulatory indication states that Apex is approved for the management of both locally advanced (more confined) as well as metastatic (more widespread) hormone-sensitive prostate cancer. This means it is indicated for use across a range of disease presentations.

Q: Do the safety warnings for Apex change for different age groups?

A: Official safety warnings note an increased risk of ischemic cardiovascular events, such as heart failure, specifically in patients aged 65 and older. Otherwise, the safety profile and contraindications generally apply across all approved adult male age groups.

Q: Is Apex known to cause weight gain or weight loss?

A: Official side effect listings include both weight gain and unusual weight loss among the reported adverse reactions observed in patients taking Apex. Any significant or unintended changes in weight are typically reviewed with a healthcare provider.

How should Apex be stored and disposed of?

How to Store and Dispose of Apex

Official regulatory guidelines strictly define the conditions for storing, handling, and disposing of Apex (Bicalutamide) to maintain its stability and ensure safety.

Requirement Official Instruction
Storage Temperature Store at controlled room temperature, between 68 F and 77 F (20 C to 25 C).
Packaging Keep the tablets in the original, labeled container to preserve the 2-year shelf life.
Child Safety Keep this and all medicines out of the sight and reach of children (FDA-mandated rule).
Special Handling Caregivers should take caution to avoid touching the pills; pregnant or nursing women must not prepare the dose.
Disposal Rule Unused or expired medication must be disposed of in accordance with local requirements (e.g., take-back programs).
Environmental Rule Do not flush down the toilet or throw in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apex found in:

A-Z Index: